Phase II / III results of the anti‐TNF multivalent NANOBODY ® compound ‘ozoralizumab’ in patient with rheumatoid arthritis ( OHZORA trial)

Authors

Keywords

Journal

Volume -, Issue -, Pages -

Publisher

Wiley

Online

2022-06-22

DOI

10.1002/art.42273

Explore over 38,000 international journals covering a vast array of academic fields.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started